

 chh_irb@chonghua.com.ph	<b>CHONG HUA HOSPITAL INSTITUTIONAL REVIEW BOARD</b>	<b>SOP/013/05</b>  <b>Effective date: 01 January 2017</b>
	<b>Title:</b>  <b>4.3 Review of Serious Adverse Event (SAE) Reports</b>	<b>Page 1 of 12</b>

ජනාතලජනාතලජනාතලජනා  
**Table of Contents**  
 ජනාතලජනාතලජනාතලජනා

No.	Content	Page No.
	Table of Contents .....	1
1.	Purpose .....	2
2.	Scope .....	2
3.	Responsibility .....	2
4.	Flowchart .....	3
5.	Detailed Instruction .....	4
5.1	Receipt & documentation of submitted reports in logbook/database .....	4
5.2	Retrieval of pertinent protocol file .....	4
5.3	Notification of Chair .....	4
5.4	Submission of report to the SAE Subcommittee/Point Person .....	4
5.5	Inclusion of report of Subcommittee in the agenda of the next IRB meeting .....	4
5.6	Communication of IRB recommendation/ action to Principal Investigator .....	4
6.	ANNEX	
	ANNEX 1	
	Serious Adverse Event Report Form .....	5
	ANNEX 2	
	Unexpected Adverse Event Report Form .....	6
	ANNEX 3	
	CIOMS Form .....	7
	ANNEX 4	
	Template for IRB reporting of SAE and SUSARs only .....	8
	ANNEX 5	
	Guidelines for Reporting Adverse Events .....	9
7.	References .....	12

 chh_irb@chonghua.com.ph	<b>CHONG HUA HOSPITAL          INSTITUTIONAL REVIEW BOARD</b>	<b>SOP/013/05</b>  <b>Effective date:          01 January 2017</b>
	<b>Title:</b> <b>4.3 Review of Serious Adverse Event (SAE)          Reports</b>	<b>Page 2 of 12</b>

### 1. Purpose

The purpose of this SOP is to ensure that the safety and welfare of human participants in the study are safeguarded and that information on SAEs and SUSARs is properly documented.

### 2. Scope

This SOP applies to the review of SAE and SUSARS reports submitted by investigators, Data Safety Monitoring Board (DSMB), sponsor, local safety monitor, CHH IRB

### 3. Responsibility







The primary responsibility of the CHH IRB is to review and address SAE and unexpected events involving risks to subjects or others as well as ethics complaints. The Chair notes the submission and ensures that the report of the SAE primary reviewer is included in the agenda of the next IRB meeting.

CHH IRB should also make sure that researchers are made aware of the policies and procedures concerning reporting and continuing review requirements.

The CHH IRB Secretariat is responsible for first screening the assessment of the reports and seeing whether they need a review by full Board, by Chairperson only, or by other qualified CHH IRB members or experts.

 chh_irb@chonghua.com.ph	<b>CHONG HUA HOSPITAL INSTITUTIONAL REVIEW BOARD</b>	<b>SOP/013/05</b>  <b>Effective date: 01 January 2017</b>
	<b>Title:</b>  <b>4.3 Review of Serious Adverse Event (SAE) Reports</b>	<b>Page 3 of 12</b>

#### 4. Flowchart

No.	ACTIVITY	RESPONSIBLE PERSONNEL
I		CHH IRB Secretariat
II		CHH IRB Secretariat
III		CHH IRB Secretariat
IV		CHH IRB members and Chairperson
V		CHH IRB members and Chairperson
VI		CHH IRB Secretariat and Chairperson

 chh_irb@chonghua.com.ph	<b>CHONG HUA HOSPITAL INSTITUTIONAL REVIEW BOARD</b>	<b>SOP/013/05</b>  <b>Effective date: 01 January 2017</b>
	<b>Title:</b> <b>4.3 Review of Serious Adverse Event (SAE) Reports</b>	<b>Page 4 of 12</b>

## 5. Detailed Instructions

### 5.1 Receipt & documentation of submitted report of SAEs and SUSARs in the logbook/ database

- Report should use the specified IRB form (**HRP-IRB-024, HRP-IRB-025 and CIOMS, see ANNEX 1-3**) and to accomplish completely and properly.
- Date of submission should be within the required timeline as mentioned in CHH IRB Guidelines.
- Record the submission in the logbook/database.

### 5.2 Retrieval of pertinent protocol file

- Retrieve pertinent information about corresponding protocol (e.g. identity of primary reviewers and earlier reports on SAEs and SUSARs)

### 5.3 Notification of Chair

- Notify thru the agenda of the next regular IRB meeting.

### 5.4 Submission of the report to SAE subcommittee or point person

- The reports should be submitted 1 – 2 weeks before the next IRB regular meeting to the SAE subcommittee or to the point person
- The specified forms should be used in presenting the SAEs and SUSARs during the regular IRB meeting

### 5.5 Inclusion of report of Subcommittee in the agenda of the next IRB meeting


- After reading and reviewing the report, the designee entertains discussion on the study and similar adverse experiences or advisories.
- If appropriate to the discussions, the Chairperson or another Board member may call for a consensus on whether to:
  - *Request further information.*
  - *Suspend or terminate the study*
  - *Take note and no further action is needed*

### 5.6 Communication of IRB recommendation/ action to Principal Investigator

- The recommendations/actions derived after the SAEs and SUSARs discussion will be communicated to the Principal Investigator/researcher according to SOP on Communicating IRB decisions.

 chh_irb@chonghua.com.ph	<b>CHONG HUA HOSPITAL INSTITUTIONAL REVIEW BOARD</b>	<b>SOP/013/05</b>  <b>Effective date: 01 January 2017</b>
	<b>Title:</b>  <b>4.3 Review of Serious Adverse Event (SAE) Reports</b>	<b>Page 5 of 12</b>

**6. ANNEX 1:**

 <b>崇華醫院 Chong Hua Hospital</b> Fuente Osmeña, Cebu City Tel# +63(32) 255-8000; Fax# +63(32) 253-5639		<p style="text-align: center;"><u>ANNEX 1</u></p> <p style="text-align: center;"><b>SERIOUS ADVERSE EVENT REPORT FORM</b></p> <p style="text-align: right;">Form HRP-IRB-024</p>	
Principal Investigator:		Protocol No.:	Application No: □□□ / □□□□ - □□
Study Title:      			
Name of the study medicine/device:		Report Date: <input type="checkbox"/> initial <input type="checkbox"/> follow-up	Onset date:
		Sponsor:	Date of first use:
Subject's initial/number:		Age:	<input type="checkbox"/> Male <input type="checkbox"/> Female
Subject's history:		Laboratory findings:	
SAE:		Treatment:	
		Outcome: <input type="checkbox"/> resolved <input type="checkbox"/> on-going	
Seriousness: <input type="checkbox"/> Death <input type="checkbox"/> Life Threatening <input type="checkbox"/> Hospitalization – <input type="checkbox"/> initial <input type="checkbox"/> prolong <input type="checkbox"/> Disability / Incapacity <input type="checkbox"/> Congenital Anomaly <input type="checkbox"/> Other		Relation to <input type="checkbox"/> Drug <input type="checkbox"/> Device <input type="checkbox"/> study <input type="checkbox"/> Not related <input type="checkbox"/> Possibly <input type="checkbox"/> Probably <input type="checkbox"/> Definitely related <input type="checkbox"/> Unknown	
Changes to the protocol recommended?		<input type="checkbox"/> No <input type="checkbox"/> Yes , attach proposal	
Changes to the informed consent form recommended?		<input type="checkbox"/> No <input type="checkbox"/> Yes , attach proposal	
Reviewed by:		Date:	
Comment:		Action:	
SERIOUS ADVERSE EVENT REPORT FORM		Page 1 of 1	



chh\_irb@chonghua.com.ph

### CHONG HUA HOSPITAL INSTITUTIONAL REVIEW BOARD

Title:


### 4.3 Review of Serious Adverse Event (SAE) Reports

SOP/013/05

Effective date:  
01 January 2017

Page 6 of 12

#### ANNEX 2:

 <b>崇華醫院</b> <b>Chong Hua Hospital</b> Fuente Osmeña, Cebu City Tel# +63(32) 255-8000; Fax# +63(32) 253-5639		<b>ANNEX 2</b>  <b>UNEXPECTED ADVERSE EVENT REPORT FORM</b>  Form HRP-IRB-025
Principal Investigator:	Protocol No.:	Application No: □□□ / □□□□ - □□
Study Title: _____ _____ _____ _____ _____		
Name of the study medicine/device:	Report Date: <input type="checkbox"/> initial <input type="checkbox"/> follow-up	Onset date:
	Sponsor:	Date of first use:
Subject's initial/number:	Age:	<input type="checkbox"/> Male <input type="checkbox"/> Female
Subject's history:	Laboratory findings:	
SAE:	Treatment:	
Seriousness: <input type="checkbox"/> Death <input type="checkbox"/> Life Threatening <input type="checkbox"/> Hospitalization - <input type="radio"/> initial <input type="radio"/> prolong <input type="checkbox"/> Disability / Incapacity <input type="checkbox"/> Congenital Anomaly <input type="checkbox"/> Other	Outcome: <input type="checkbox"/> resolved <input type="checkbox"/> on-going Relation to <input type="radio"/> Drug <input type="radio"/> Device <input type="radio"/> study <input type="checkbox"/> Not related <input type="checkbox"/> Possibly <input type="checkbox"/> Probably <input type="checkbox"/> Definitely related <input type="checkbox"/> Unknown	
	Changes to the protocol recommended? <input type="checkbox"/> No <input type="checkbox"/> Yes, attach proposal Changes to the informed consent form recommended? <input type="checkbox"/> No <input type="checkbox"/> Yes, attach proposal	
Reviewed by:	Date:	
Comment:	Action:	

UNEXPECTED ADVERSE EVENT REPORT FORM Page 1 of 1



chh\_irb@chonghua.com.ph

# CHONG HUA HOSPITAL INSTITUTIONAL REVIEW BOARD

Title:


## 4.3 Review of Serious Adverse Event (SAE) Reports

SOP/013/05

Effective date:  
01 January 2017

Page 7 of 12

### ANNEX 3:



 院醫華榮福指 <b>Chong Hua Hospital</b> Fuente Osmeña, Cebu City Telf +85(32) 255-0000, Fax# +85(32) 255-0839		<b>ANNEX 3</b> <b>CIOMS FORM</b>													
<b>I. REACTION INFORMATION</b>															
<b>SUSPECT ADVERSE REACTION REPORT</b>			<table border="1" style="width: 100%; height: 40px;"> <tr> <td style="width: 10%;"></td> <td style="width: 10%;"></td> <td style="width: 10%;"></td> <td style="width: 10%;"></td> <td style="width: 10%;"></td> <td style="width: 10%;"></td> <td style="width: 10%;"></td> <td style="width: 10%;"></td> <td style="width: 10%;"></td> <td style="width: 10%;"></td> <td style="width: 10%;"></td> <td style="width: 10%;"></td> </tr> </table>												
1. PATIENT INITIALS <small>(first, last)</small>	1a. COUNTRY	2. DATE OF BIRTH <small>Day Month Year</small>	2.a AGE <small>Years</small>	3. SEX	4-6 REACTION ONSET <small>Day Month Year</small>	8-12 CHECK ALL APPROPRIATE TO ADVERSE REACTION									
7 + 13 DESCRIBE REACTIONS (including relevant test/lab data)						<input type="checkbox"/> PATIENT DIED <input type="checkbox"/> INVOLVED OR PROLONGED INPATIENT HOSPITALISATION <input type="checkbox"/> INVOLVED PERSISTENCE OF SIGNIFICANT DISABILITY OR INCAPACITY <input type="checkbox"/> LIFE THREATENING									
<b>II. SUSPECT DRUG(S) INFORMATION</b>															
14. SUSPECT DRUG(S) (include generic name)			20. DID REACTION ABATE AFTER STOPPING DRUG? <input type="checkbox"/> YES <input type="checkbox"/> NO <input type="checkbox"/> NA												
15. DAILY DOSE(S)		16. ROUTE(S) OF ADMINISTRATION		21. DID REACTION REAPPEAR AFTER REINTRODUCTION? <input type="checkbox"/> YES <input type="checkbox"/> NO <input type="checkbox"/> NA											
17. INDICATION(S) FOR USE															
18. THERAPY DATE (from/to)		19. THERAPY DURATION													
<b>III. CONCOMITANT DRUG(S) AND HISTORY</b>															
22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction)															
23. OTHER RELEVANT HISTORY (e.g. diagnostics, allergies, pregnancy with last month of period, etc.)															
<b>IV. MANUFACTURER INFORMATION</b>															
24a. NAME AND ADDRESS OF MANUFACTURER		24b. MFR CONTROL NO.													
24c. DATE RECEIVED BY MANUFACTURER		24d. REPORT SOURCE <input type="checkbox"/> STUDY <input type="checkbox"/> LITERATURE <input type="checkbox"/> HEALTH PROFESSIONAL													
DATE OF THIS REPORT		25a. REPORT TYPE <input type="checkbox"/> INITIAL <input type="checkbox"/> FOLLOWUP													
<small>Institutional Review Board</small>		<small>CHONG HUA HOSPITAL</small>													





 chh_irb@chonghua.com.ph	<b>CHONG HUA HOSPITAL INSTITUTIONAL REVIEW BOARD</b>	<b>SOP/013/05</b>  <b>Effective date: 01 January 2017</b>
	<b>Title:</b>  <b>4.3 Review of Serious Adverse Event (SAE) Reports</b>	<b>Page 9 of 12</b>

## ANNEX 5: Guidelines for Reporting Adverse Events


Institutional Review Board


---

**CHONG HUA HOSPITAL**  
 Don Mariano Cui St., corner J. Lorente St., Cebu City, Philippines 6000  
 ☎ 255-8000 (local 7434); Email: [chh\\_irb@chonghua.com.ph](mailto:chh_irb@chonghua.com.ph)

---

### Guidelines for Reporting Adverse Events

Per requirements of the Food and Drug Administration (FDA) the following serves as a guide for the reporting of adverse events within or outside the Chong Hua Hospital System.

**Definition of Terms:**

An Adverse Event (AE) is any undesirable experience or any adverse change in health or "side-effect" which is unintended, although not necessarily unexpected that occurs in a subject who participates in a clinical trial while the subject is receiving the treatment (study medication, application of the study device, etc.) or within a pre-specified period of time after their treatment has been completed.

A Serious Adverse Event (SAE) in human drug trials is defined as any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of ongoing hospitalization, results in persistent or significant disability/incapacity, or is a congenital anomaly/birth defect.

An Unexpected Adverse Experience (UAE) is any adverse experience associated with the use of the drug/device, the specificity or severity of which is not consistent with the current investigator brochure; or, if an investigator brochure is not required or available, the specificity or severity of which is not consistent with the risk information provided to subjects (in the Informed Consent Document) and the IRB.

A Related adverse event occurs when there is a reasonable possibility that the adverse event is caused by the research activity (drug/device/procedure).

The relationship of the Adverse Events to the Investigational Product, Study drug, device or procedure is left to the discretion of the Primary Investigator of the study. Likewise it is the responsibility of the Principal Investigator to decide if the event warrants a change to the protocol to minimize risks and/or the informed consent form to better inform subjects of the potential risks and procedures to minimize such risks.

**On Site Adverse Events**  
*On Site adverse event is any untoward medical occurrence in a patient or clinical investigation participant which happens under the study conducted inside CHH Research Facility Unit. An adverse event that meets any of the following criteria must be reported to the CHH IRB.*

Chong Hua Hospital – Institutional Review Board
Ver12\_010117
Page 9 of 15



chh\_irb@chonghua.com.ph

## CHONG HUA HOSPITAL INSTITUTIONAL REVIEW BOARD

Title:

### 4.3 Review of Serious Adverse Event (SAE) Reports

SOP/013/05

Effective date:  
01 January 2017

Page 10 of 12



## *Institutional Review Board*

CHONG HUA HOSPITAL

Don Mariano Cui St., corner J. Llorente St., Cebu City, Philippines 6000

☎ 255-8000 (local 7434); Email: [chh\\_irb@chonghua.com.ph](mailto:chh_irb@chonghua.com.ph)



#### ***Reporting requirement***

1. The event is Serious or Unexpected, and Related to the research activity.
2. If the event is Related, Expected or not Serious but in the opinion of the investigator the protocol and/or informed consent form requires modification. Examples: identification of a "new trend" (adverse event occurring with greater frequency than anticipated) or a change in the risk/benefit ratio.
3. All non serious adverse events regardless of the relationship to the study drug.

#### ***Timelines for reporting***

1. Serious and related AEs must be reported within 24 hours after discovery.
2. Serious but unrelated AEs must be reported within 2 weeks after discovery.
3. If the event is Related, Expected or not Serious but in the opinion of the investigator the protocol and/or informed consent form requires modification. Examples: identification of a "new trend" (adverse event occurring with greater frequency than anticipated) or a change in the risk/benefit ratio the event must be reported within 2 weeks after discovery.
4. All other non serious AEs must be reported within 24 weeks after discovery.

#### **Off Site Adverse Events**

##### ***Reporting requirement***

An Off Site adverse event is any untoward medical occurrence in a patient or clinical investigation participant which happens under the study conducted outside CHH Research Facility Unit. These may include sponsor provided adverse events reports. An Off Site event that meets any of the following criteria must be reported to the CHH IRB:

1. The event is Serious or Unexpected and Related to the submitted research.
2. For a study not conducted at CHH, submit only those event reports that require a change in the submitted protocol and/or informed consent form.

##### ***Timelines for reporting***

1. Serious and related AEs must be reported within 2 weeks after discovery.
2. Serious but unrelated AEs may be reported within 4 weeks after discovery.
3. Events that require a protocol or informed consent form modification must be reported within 2 weeks upon receipt from the study sponsor.
4. All other non serious AEs may be reported within 48 weeks after discovery.



chh\_irb@chonghua.com.ph

## CHONG HUA HOSPITAL INSTITUTIONAL REVIEW BOARD

Title:

### 4.3 Review of Serious Adverse Event (SAE) Reports

SOP/013/05

Effective date:  
01 January 2017

Page 11 of 12



## *Institutional Review Board*

CHONG HUA HOSPITAL

Don Mariano Cui St., corner J. Llorente St., Cebu City, Philippines 6000  
☎ 255-8000 (local 7434); Email: [chh\\_irb@chonghua.com.ph](mailto:chh_irb@chonghua.com.ph)



#### How to Submit an Adverse Event Form

1. For reporting of the Adverse Events/Reactions the investigator may use the CIOMS or any other similar form deemed appropriate by the investigator.
2. On Report form should be accomplished per event.
3. Incomplete forms will be returned to the investigator for completion.
4. Provide a brief description/summary of the adverse event.
5. Attach pertinent supporting documents (e.g., hospitalization summary) as needed.
6. The IRB expects regular updates from the reported Adverse Events and the resolution of the Serious Adverse Drug Reaction/s reported.

N.B.: There are situations where a serious or unexpected adverse event requires an immediate change to a protocol in order to eliminate apparent immediate hazards to research subjects. In these situations, the principal investigator may immediately implement a protocol change necessary to protect the welfare of the research subjects without a CHH IRB approved amendment. Investigators are required to notify the IRB in writing of the change, within 7 working days, and include a written description of the change and events that necessitated immediate implementation. The investigator must indicate in the report whether a change to the protocol and/or informed consent is necessary.

 chh_irb@chonghua.com.ph	<b>CHONG HUA HOSPITAL          INSTITUTIONAL REVIEW BOARD</b>	<b>SOP/013/05</b>  <b>Effective date:          01 January 2017</b>
	<b>Title:</b> <b>4.3 Review of Serious Adverse Event (SAE)          Reports</b>	<b>Page 12 of 12</b>

## 7. References

- ❖ World Health Organization, Operational Guidelines for Ethics Committees that Review Biomedical Research, 2000.
- ❖ International Conference on Harmonization, Guidance on Good Clinical Practice (ICH GCP) 1996.
- ❖ National Ethical Guidelines for Health Research 2011 PNHRs
- ❖ Philippine Health Research Ethics Board, Workbook for Developing Standard Operating Procedures